A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A

A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A

Background Despite recent advances, factor replacement therapy remains a cornerstone in hemophilia A treatment. Efmoroctocog alfa, a recombinant FVIII Fc fusion protein (rFVIIIFc), has an extended half-life allowing higher FVIII levels and less frequent dosing than standard half-life (SHL) products,...

Full description

Saved in:
Bibliographic Details
Main Authors: Johannes Oldenburg, Charles Hay, Flora Peyvandi, Anna-Elina Lehtinen, Ingrid Pabinger, Eveline Nüesch, Håkan Malmström, Eva Bednar, Stefan Lethagen
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Hematology
Subjects:
Hemophilia A
standard half-life
extended half-life
factor consumption
injection frequency
real-world
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2025.2513186
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2025.2513186

Similar Items